384 related articles for article (PubMed ID: 16300416)
1. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data.
Margolis J; Barron JJ; Grochulski WD
J Manag Care Pharm; 2005; 11(9):727-34. PubMed ID: 16300416
[TBL] [Abstract][Full Text] [Related]
2. Disease-related and all-cause health care costs of elderly patients with gout.
Wu EQ; Patel PA; Yu AP; Mody RR; Cahill KE; Tang J; Krishnan E
J Manag Care Pharm; 2008 Mar; 14(2):164-75. PubMed ID: 18331118
[TBL] [Abstract][Full Text] [Related]
3. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective.
McAdam-Marx C; McGarry LJ; Hane CA; Biskupiak J; Deniz B; Brixner DI
J Manag Care Pharm; 2011 Sep; 17(7):531-46. PubMed ID: 21870894
[TBL] [Abstract][Full Text] [Related]
4. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
[TBL] [Abstract][Full Text] [Related]
5. Comparative Assessment of Medical Resource Use and Costs Associated with Patients with Symptomatic Peripheral Artery Disease in the United States.
Chase MR; Friedman HS; Navaratnam P; Heithoff K; Simpson RJ
J Manag Care Spec Pharm; 2016 Jun; 22(6):667-75. PubMed ID: 27231794
[TBL] [Abstract][Full Text] [Related]
6. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
[TBL] [Abstract][Full Text] [Related]
7. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database.
Prescott JD; Factor S; Pill M; Levi GW
J Manag Care Pharm; 2007; 13(1):44-52. PubMed ID: 17269836
[TBL] [Abstract][Full Text] [Related]
8. Total first-year costs of acute coronary syndrome in a managed care setting.
Etemad LR; McCollam PL
J Manag Care Pharm; 2005 May; 11(4):300-6. PubMed ID: 15871640
[TBL] [Abstract][Full Text] [Related]
9. Actuarial analysis of private payer administrative claims data for women with endometriosis.
Mirkin D; Murphy-Barron C; Iwasaki K
J Manag Care Pharm; 2007 Apr; 13(3):262-72. PubMed ID: 17407392
[TBL] [Abstract][Full Text] [Related]
10. Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients.
Bickston SJ; Waters HC; Dabbous O; Tang BI; Rahman M
J Manag Care Pharm; 2008 May; 14(4):352-62. PubMed ID: 18500913
[TBL] [Abstract][Full Text] [Related]
11. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
[TBL] [Abstract][Full Text] [Related]
12. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
13. Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection.
Tencer T; Friedman HS; Li-McLeod J; Johnson K
J Manag Care Pharm; 2007; 13(9):790-8. PubMed ID: 18062730
[TBL] [Abstract][Full Text] [Related]
14. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy.
Yokoyama K; Yang W; Preblick R; Frech-Tamas F
J Manag Care Pharm; 2007 Apr; 13(3):235-44. PubMed ID: 17407390
[TBL] [Abstract][Full Text] [Related]
15. Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization.
Mitchell MP; Schaecher K; Cannon HE; Speckman M
J Manag Care Pharm; 2008 Jun; 14(5):442-50. PubMed ID: 18597573
[TBL] [Abstract][Full Text] [Related]
16. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.
Menzin J; Korn JR; Cohen J; Lobo F; Zhang B; Friedman M; Neumann PJ
J Manag Care Pharm; 2010 May; 16(4):264-75. PubMed ID: 20433217
[TBL] [Abstract][Full Text] [Related]
17. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
[TBL] [Abstract][Full Text] [Related]
18. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
Khandker RK; Kruzikas DT; McLaughlin TP
J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
[TBL] [Abstract][Full Text] [Related]
19. Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease.
Gandra SR; Lawrence LW; Parasuraman BM; Darin RM; Sherman JJ; Wall JL
J Manag Care Pharm; 2006 Sep; 12(7):546-54. PubMed ID: 16981800
[TBL] [Abstract][Full Text] [Related]
20. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.
Laliberté F; Bookhart BK; Vekeman F; Corral M; Duh MS; Bailey RA; Piech CT; Lefebvre P
J Manag Care Pharm; 2009 May; 15(4):312-22. PubMed ID: 19422271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]